Availability of the Q4 2021 Memorandum for modelling purposes
04 Januar 2022 - 07:30AM
Availability of the Q4 2021 Memorandum for modelling purposes
Availability of the
Q4 2021 Memorandum for modelling
purposes
Paris, France –
January 4,
2022 - Sanofi announced
today that its Q4 2021 Memorandum for modelling purposes is
available on the "Investors" page of the company's
website:https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q4-results-2021
As for each quarter, Sanofi prepared this
document to assist in the financial modelling of the Group's
quarterly results. This document includes a reminder on various
non-comparable items and exclusivity losses as well as the foreign
currency impact and share count. Sanofi's fourth-quarter 2021
results will be published on February 4, 2022.
About Sanofi
Sanofi is dedicated to supporting people through
their health challenges. We are a global biopharmaceutical company
focused on human health. We prevent illness with vaccines, provide
innovative treatments to fight pain and ease suffering. We stand by
the few who suffer from rare diseases and the millions with
long-term chronic conditions.
With more than 100,000 people in 100 countries,
Sanofi is transforming scientific innovation into healthcare
solutions around the globe.
Media Relations
ContactsSandrine GuendoulTel.: +33 (0)6 25 09 14
25sandrine.guendoul@sanofi.com
Media Relations main line:Tel.: +33 (0)1 53 77
46 46mr@sanofi.com
Investor Relations Contacts
ParisEva Schaefer-JansenArnaud DelépineNathalie Pham
Investor Relations Contacts North
AmericaFelix Lauscher
Investor Relations Main Line:Tel.: +33 (0)1 53
77 45
45investor.relations@sanofi.comhttps://www.sanofi.com/en/investors/contact
Sanofi Forward-Looking
StatementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post
marketing, decisions by regulatory authorities, such as the FDA or
the EMA, regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi’s
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such litigation,
trends in exchange rates and prevailing interest rates, volatile
economic and market conditions, cost containment initiatives and
subsequent changes thereto, and the impact that COVID-19 will have
on us, our customers, suppliers, vendors, and other business
partners, and the financial condition of any one of them, as well
as on our employees and on the global economy as a whole. Any
material effect of COVID-19 on any of the foregoing could also
adversely impact us. This situation is changing rapidly and
additional impacts may arise of which we are not currently aware
and may exacerbate other previously identified risks. The risks and
uncertainties also include the uncertainties discussed or
identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under “Risk Factors” and “Cautionary
Statement Regarding Forward-Looking Statements” in Sanofi’s annual
report on Form 20-F for the year ended December 31, 2020. Other
than as required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
- 22-01-04 - Press Release - ENG
Sanofi (BIT:1SAN)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Sanofi (BIT:1SAN)
Historical Stock Chart
Von Mär 2023 bis Mär 2024